Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05218889

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer: a Prospective, Randomized Controlled Clinical Trial

Sponsor: Chinese PLA General Hospital

Conditions PDAC - Pancreatic Ductal Adenocarcinoma Pancreas Cancer Pancreatic Cancer Pancreatic Neoplasms

Interventions nab-paclitaxel + gemcitabine surufatinib + camrelizumab + nab-paclitaxel + S-1

Updated 6 times since 2022 Last updated: Dec 28, 2024 Started: Aug 4, 2021 Primary completion: Dec 16, 2024 Completion: Jun 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05218889, this PHASE1/PHASE2 trial focuses on PDAC - Pancreatic Ductal Adenocarcinoma and Pancreas Cancer and remains actively recruiting participants. Sponsored by Chinese PLA General Hospital, it has been updated 6 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Feb 2025 — Present [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Sep 2022 — May 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting · Phase: PHASE2 → PHASE1_PHASE2

▶ Show 1 earlier version

Feb 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese PLA General Hospital

Data source: Chinese PLA General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China